Xarelto(Bayer/Johnson &Johnson) success in ATLAS ACS 2 TIMI 51 study in Acute Coronary Syndrome

Xarelto (rivaroxaban) from Bayer/Johnson & Johnson twice daily with standard anti- platelet therapy significantly reduced both the rate of cardiovascular death, myocardial infarction and stroke in Acute Coronary Syndrome patients compared to those receiving standard anti-platelet therapy alone. In addition Xarelto 2.5 mg in combination with standard therapy significantly reduced mortality. Results from the ATLAS ACS 2-TIMI 51 study were presented at the American Heart Association meeting and published in the NEJM. Xarelto significantly reduced the rate of major bleeding but did not increase the risk of fatal bleeding over standard therapy alone. C.Michael Gibson the principal investigator of the ATLAS ACS studies commented that if data from this study were extrapolated into clinical practise we could potentially see one life saved for every 56 patients treated with the new combination over a two year period. The FDA has granted Xarelto Fast Track status and it is intended to submit an application for approval to the FDA this year. see Rivaroxaban after Acute Coronary Syndrome November 13, 2011 | J.L. Mega and Others (DOI: 10.1056/NEJMoa1112277